Executive Summary (Q2 2025): Agape ATP Corporation delivered pronounced revenue growth in QQ2 2025, with reported revenue of 465,499 and a gross profit of 208,940, yielding a gross margin of approximately 44.9%. This top-line expansion reflects deeper penetration of Agape ATP’s health and wellness programs and product lines, including ATP-series offerings, BEAUNIQUE, and ENERGETIQUE variants, as well as the BEAUNIQUE Mito antioxidant and ORYC Organic Youth Care lines. However, the quarter remained enveloped in meaningful profitability headwinds. Operating income came in at -636,961 and EBITDA at -592,725, resulting in an EBITDARatio of -1.27x and an EBITDA-driven margin that confirms the business is in a loss position at the operating level. Net income registered -617,078 with a net margin of -1.33%, and basic EPS stood at -0.0123. The company maintains a robust liquidity profile with cash and cash equivalents of 215,973 and total current assets of 24,345,513, supporting a strong current ratio of 20.35x. Yet, the balance sheet carries a substantial non-operating asset base (notably a large “Other Current Assets” line) that masks the underlying cash burn in operating activities. Net debt remains modest at 77,063, while retained earnings are negative at -10,834,072, underscoring sustained accumulated losses despite equity exceeding 23.4 million. The quarter’s YoY/QoQ metrics show revenue up 48.7% YoY and 61.1% QoQ; gross profit up 7.95% YoY and 33.69% QoQ, but operating and net profitability remain negative. The investment takeaway is a cautious stance: near-term upside hinges on a sustained improvement in operating leverage and cash flow generation, while the current quarter emphasizes continued investment in portfolio expansion and brand-building across the health and wellness ecosystem.